Cargando…

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study

Detalles Bibliográficos
Autores principales:	Garcia, Jose M, Yan, Ying, Manning-Duus, Elizabeth, Friend, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073088/ http://dx.doi.org/10.1186/2049-3002-2-S1-P19

Ejemplares similares

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
por: Northrup, R., et al.
Publicado: (2013)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

Acylated Ghrelin Receptor Agonist HM01 Decreases Lean Body and Muscle Mass, but Unacylated Ghrelin Protects against Redox-Dependent Sarcopenia
por: Ranjit, Rojina, et al.
Publicado: (2022)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
por: Currow, David C., et al.
Publicado: (2018)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia
por: Murphy, R A, et al.
Publicado: (2011)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
por: Taniguchi, Jumpei, et al.
Publicado: (2023)

Chronic Renal Failure, Cachexia, and Ghrelin
por: Laviano, A., et al.
Publicado: (2010)

Novel mechanism of ghrelin therapy for cachexia
por: Hatanaka, Michiyoshi, et al.
Publicado: (2015)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
por: Strasser, F, et al.
Publicado: (2008)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
por: T. de Barros, Cecilia, et al.
Publicado: (2020)

Chemotherapy-induced cachexia and model-informed dosing to preserve lean mass in cancer treatment
por: Farhang-Sardroodi, Suzan, et al.
Publicado: (2022)

Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia
por: Müller, Timo D., et al.
Publicado: (2010)

Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014)

Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017)

Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient‐reported outcomes in pancreatic cancer cachexia
por: Gresham, Gillian, et al.
Publicado: (2021)

Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors
por: Villars, Fabienne O., et al.
Publicado: (2017)

The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
por: Wakabayashi, Hidetaka, et al.
Publicado: (2020)

Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment
por: Miki, Keisuke, et al.
Publicado: (2013)

Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011)

Natural ghrelin in advanced cancer patients with cachexia, a case series
por: Blum, David, et al.
Publicado: (2021)

FTO Variant rs1421085 Associates With Increased Body Weight, Soft Lean Mass, and Total Body Water Through Interaction With Ghrelin and Apolipoproteins in Arab Population
por: Hebbar, Prashantha, et al.
Publicado: (2020)

Metabolism Study of Anamorelin, a GHSR1a Receptor Agonist Potentially Misused in Sport, with Human Hepatocytes and LC-HRMS/MS
por: Gameli, Prince Sellase, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8gfvn6mck0kuaae3pvbge9um6n